Licensing analysis: Takeda saves the day
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
Bristol overtakes Amgen in colorectal
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
A new menin challenger
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
Bristol backs out of BET inhibition
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
GenFleet bids to join the colorectal KRAS crowd
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.
A cancer pipeline cull from AbbVie
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
